Top

BY Simona Colla, Ph.D.

Growing up in Italy, I found my happy place with science. Even when dealing with a challenging home life, science offered an escape. But I didn’t get my start in research until later in life.  

Now, as a principal investigator with my own lab at MD Anderson, I work with a talented group of researchers focused on myelodysplastic syndrome, specifically how it develops and becomes resistant to treatment. My lab is my life...

Myelodysplastic syndrome researcher Simona Colla, Ph.D., stands in the lab as other researchers work.

BY Meagan Raeke

“Every community is unique,” says Ruth Rechis, Ph.D., director of Be Well Communities™, MD Anderson’s place-based strategy...

BY Clayton Boldt, Ph.D.

Scientific discoveries are essential to driving advances in cancer care. From better screening and diagnostic techniques to innovative new...

BY Shanley Chien

Since the discovery of KRAS gene mutations in 1983, researchers have worked to develop new therapies that target this protein when treating cancer. Unfortunately, KRAS mutations have long been considered impossible to treat with drugs, but MD Anderson researchers have made recent breakthroughs in developing targeted therapies with promising results.

Shubham Pant, M.D., associate professor of Investigational Cancer Therapeutics...

Illustration of the KRAS mutation

BY Devon Carter

B-cell lymphoma isn’t one disease. There are about 63 subtypes, with diffuse large B-cell lymphoma (DLBCL) being the most common. A chemotherapy...

BY Devon Carter

Last updated Jan. 11, 2022.

First emerging almost three decades ago, monoclonal antibodies are changing the way doctors treat cancer...

BY Clayton Boldt, Ph.D.

In the last decade, immunotherapy has become a viable treatment option for many cancer patients. Unlike radiation and chemotherapy, immunotherapy...

BY Clayton Boldt, Ph.D.

After completing a course of treatment, there are few words that sound better to a patient than “complete remission.” It’s an indication that...

BY Devon Carter

Natural killer cells – or NK cells – are part of our immune system. They patrol our bodies for abnormal cells like cancer and destroy them...

BY Cynthia DeMarco

Lori Shults didn’t know much about clinical trials when she first came to MD Anderson in May 2017. “I thought they involved some people getting...